Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.

Shen YT, Wang L, Evans JC, Allen C, Piquette-Miller M.

Int J Mol Sci. 2019 May 21;20(10). pii: E2498. doi: 10.3390/ijms20102498.

2.

Poly(I:C) alters placental and fetal brain amino acid transport in a rat model of maternal immune activation.

McColl ER, Piquette-Miller M.

Am J Reprod Immunol. 2019 Jun;81(6):e13115. doi: 10.1111/aji.13115. Epub 2019 Apr 15.

PMID:
30924965
3.

Dysregulation of solute carrier transporters in malaria-infected pregnant mice.

Najjar N, McColl ER, Weckman A, Kain KC, Piquette-Miller M.

Parasite Immunol. 2019 Apr;41(4):e12614. doi: 10.1111/pim.12614. Epub 2019 Feb 20.

PMID:
30703256
4.

STAT3 is involved in IL-6-Mediated Downregulation of Hepatic Transporters in Mice.

Abualsunun WA, Piquette-Miller M.

J Pharm Pharm Sci. 2018;21(1s):325s-334s. doi: 10.18433/jpps30241.

5.

Battling the HIV/AIDS Epidemic: Triumphs and Barriers.

McColl ER, Kojovic D, Piquette-Miller M.

Clin Pharmacol Ther. 2018 Dec;104(6):1042-1046. doi: 10.1002/cpt.1202.

PMID:
30412658
6.

User considerations in assessing pharmacogenomic tests and their clinical support tools.

Mukerjee G, Huston A, Kabakchiev B, Piquette-Miller M, van Schaik R, Dorfman R.

NPJ Genom Med. 2018 Sep 11;3:26. doi: 10.1038/s41525-018-0065-4. eCollection 2018. Review.

7.

Endotoxin Modulates the Expression of Renal Drug Transporters in HIV-1 Transgenic Rats.

Karimian Pour N, Piquette-Miller M.

J Pharm Pharm Sci. 2018;21(1s):117s-129s. doi: 10.18433/jpps30017.

8.

Meta-Analysis of Pregnancy Outcomes after Exposure to TNF-α Inhibitors During Pregnancy for the Treatment of Arthritic Diseases.

Mirdamadi K, Salinas T, Vali R, Papadimitropoulos M, Piquette-Miller M.

J Popul Ther Clin Pharmacol. 2018 Apr 10;25(1):e53-e56. doi: 10.22374/1710-6222.25.1.5.

PMID:
29949681
9.

Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):900-915. doi: 10.1002/cpt.1115. Epub 2018 Jul 12.

PMID:
29756222
10.

BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.

Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.

Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.

PMID:
29750868
11.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30. Review.

12.

Response to 'Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives'.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL.

Br J Clin Pharmacol. 2018 Mar;84(3):604. doi: 10.1111/bcp.13487. Epub 2018 Jan 6. No abstract available.

13.

Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.

Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.

Mol Pharm. 2018 Feb 5;15(2):472-485. doi: 10.1021/acs.molpharmaceut.7b00843. Epub 2018 Jan 22.

PMID:
29283581
14.

Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer.

Winocur G, Berman H, Nguyen M, Binns MA, Henkelman M, van Eede M, Piquette-Miller M, Sekeres MJ, Wojtowicz JM, Yu J, Zhang H, Tannock IF.

Neuroscience. 2018 Jan 15;369:51-65. doi: 10.1016/j.neuroscience.2017.10.048. Epub 2017 Nov 4.

PMID:
29113931
15.

The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice.

Gahir SS, Piquette-Miller M.

Pharmaceutics. 2017 Oct 24;9(4). pii: E49. doi: 10.3390/pharmaceutics9040049.

16.

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.

Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM.

Clin Pharmacol Ther. 2018 May;103(5):854-867. doi: 10.1002/cpt.807. Epub 2017 Oct 9.

17.

Involvement of Nuclear Factor κB, not Pregnane X Receptor, in Inflammation-Mediated Regulation of Hepatic Transporters.

Abualsunun WA, Piquette-Miller M.

Drug Metab Dispos. 2017 Oct;45(10):1077-1083. doi: 10.1124/dmd.117.076927. Epub 2017 Aug 4. Erratum in: Drug Metab Dispos. 2017 Nov;45(11):1148.

PMID:
28778997
18.

Within Our Skin.

Salinas T, Piquette-Miller M.

Clin Pharmacol Ther. 2017 Jul;102(1):8-12. doi: 10.1002/cpt.708.

PMID:
30239991
19.

Aprepitant and fosaprepitant drug interactions: a systematic review.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL.

Br J Clin Pharmacol. 2017 Oct;83(10):2148-2162. doi: 10.1111/bcp.13322. Epub 2017 Jun 10. Review.

20.

Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access.

Rekić D, Reynolds KS, Zhao P, Zhang L, Yoshida K, Sachar M, Piquette Miller M, Huang SM, Zineh I.

J Pharm Sci. 2017 Sep;106(9):2214-2218. doi: 10.1016/j.xphs.2017.04.016. Epub 2017 Apr 21. Review.

PMID:
28435142
21.

Impact of endotoxin on the expression of drug transporters in the placenta of HIV-1 transgenic (HIV-Tg) rats.

Ghoneim RH, Kojovic D, Piquette-Miller M.

Eur J Pharm Sci. 2017 May 1;102:94-102. doi: 10.1016/j.ejps.2017.03.004. Epub 2017 Mar 6.

PMID:
28274777
22.

The Bugs Within Our Body: The Human Microbiota.

Philpott DJ, Piquette-Miller M.

Clin Pharmacol Ther. 2016 Jun;99(6):570-4. doi: 10.1002/cpt.371.

PMID:
27160649
23.

Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats.

Ghoneim RH, Piquette-Miller M.

Drug Metab Dispos. 2016 May;44(5):709-19. doi: 10.1124/dmd.115.067827. Epub 2016 Mar 14.

PMID:
26977098
24.

Maternal bacterial infections impact expression of drug transporters in human placenta.

Petrovic V, Kojovic D, Cressman A, Piquette-Miller M.

Int Immunopharmacol. 2015 Jun;26(2):349-56. doi: 10.1016/j.intimp.2015.04.020. Epub 2015 Apr 21.

PMID:
25912346
25.

Polyinosinic/Polycytidylic Acid-mediated changes in maternal and fetal disposition of lopinavir in rats.

Petrovic V, Piquette-Miller M.

Drug Metab Dispos. 2015 Jul;43(7):951-7. doi: 10.1124/dmd.114.062315. Epub 2015 Apr 17.

PMID:
25887454
26.

Blood-brain barrier: an impediment to neuropharmaceuticals.

Henderson JT, Piquette-Miller M.

Clin Pharmacol Ther. 2015 Apr;97(4):308-13. doi: 10.1002/cpt.77. Epub 2015 Feb 24.

PMID:
25670372
27.

Effect of a high-fat diet on the hepatic expression of nuclear receptors and their target genes: relevance to drug disposition.

Ghoneim RH, Ngo Sock ET, Lavoie JM, Piquette-Miller M.

Br J Nutr. 2015 Feb 14;113(3):507-16. doi: 10.1017/S0007114514003717. Epub 2015 Jan 23.

PMID:
25612518
28.

Inflammation: the dynamic force of health and disease.

Vassileva V, Piquette-Miller M.

Clin Pharmacol Ther. 2014 Oct;96(4):401-5. doi: 10.1038/clpt.2014.150.

PMID:
25236660
29.

The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs.

Dubbelboer IR, Lilienberg E, Hedeland M, Bondesson U, Piquette-Miller M, Sjögren E, Lennernäs H.

Mol Pharm. 2014 Apr 7;11(4):1301-13. doi: 10.1021/mp4007612. Epub 2014 Mar 7.

PMID:
24558959
30.

Malaria infection alters the expression of hepatobiliary and placental drug transporters in pregnant mice.

Cressman AM, McDonald CR, Silver K, Kain KC, Piquette-Miller M.

Drug Metab Dispos. 2014 Apr;42(4):603-10. doi: 10.1124/dmd.113.053983. Epub 2013 Nov 26.

PMID:
24281836
31.

Network medicine: finding the links to personalized therapy.

Chen JY, Piquette-Miller M, Smith BP.

Clin Pharmacol Ther. 2013 Dec;94(6):613-6. doi: 10.1038/clpt.2013.195.

PMID:
24241633
32.

The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice.

Fardell JE, Zhang J, De Souza R, Vardy J, Johnston I, Allen C, Henderson J, Piquette-Miller M.

Psychopharmacology (Berl). 2014 Mar;231(5):841-52. doi: 10.1007/s00213-013-3301-8. Epub 2013 Oct 8.

PMID:
24101158
33.

Continuous intraperitoneal carboplatin delivery for the treatment of late-stage ovarian cancer.

Zhidkov N, De Souza R, Ghassemi AH, Allen C, Piquette-Miller M.

Mol Pharm. 2013 Sep 3;10(9):3315-22. doi: 10.1021/mp400345h. Epub 2013 Aug 21.

PMID:
23924289
34.

Epigenetics: a new link toward understanding human disease and drug response.

Cressman AM, Piquette-Miller M.

Clin Pharmacol Ther. 2012 Dec;92(6):669-73. doi: 10.1038/clpt.2012.179.

PMID:
23160355
35.

Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.

Anger GJ, Cressman AM, Piquette-Miller M.

PLoS One. 2012;7(4):e35027. doi: 10.1371/journal.pone.0035027. Epub 2012 Apr 27.

36.

Recent advances in drug delivery strategies for treatment of ovarian cancer.

Zahedi P, Yoganathan R, Piquette-Miller M, Allen C.

Expert Opin Drug Deliv. 2012 May;9(5):567-83. doi: 10.1517/17425247.2012.665366. Epub 2012 Mar 27. Review.

PMID:
22452661
37.

An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.

Zahedi P, Stewart J, De Souza R, Piquette-Miller M, Allen C.

J Control Release. 2012 Mar 28;158(3):379-85. doi: 10.1016/j.jconrel.2011.11.025. Epub 2011 Nov 26.

PMID:
22154933
38.

Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.

Cressman AM, Petrovic V, Piquette-Miller M.

Expert Rev Clin Pharmacol. 2012 Jan;5(1):69-89. doi: 10.1586/ecp.11.66. Review.

PMID:
22142160
39.

Optimizing cancer care: is the future bright?

Zahedi P, De Souza R, Piquette-Miller M.

Clin Pharmacol Ther. 2011 Sep;90(3):347-50. doi: 10.1038/clpt.2011.167. No abstract available.

PMID:
21862960
40.

Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes.

Anger GJ, Piquette-Miller M.

Drug Metab Dispos. 2011 Oct;39(10):1850-9. doi: 10.1124/dmd.111.040626. Epub 2011 Jul 8.

PMID:
21742899
41.

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.

De Souza R, Zahedi P, Badame RM, Allen C, Piquette-Miller M.

Mol Cancer Ther. 2011 Jul;10(7):1289-99. doi: 10.1158/1535-7163.MCT-11-0058. Epub 2011 May 6.

42.

Docetaxel distribution following intraperitoneal administration in mice.

Zahedi P, De Souza R, Piquette-Miller M, Allen C.

J Pharm Pharm Sci. 2011;14(1):90-9.

43.

Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer.

Zahedi P, De Souza R, Huynh L, Piquette-Miller M, Allen C.

Mol Pharm. 2011 Feb 7;8(1):260-9. doi: 10.1021/mp100323z. Epub 2010 Dec 17.

PMID:
21166459
44.

Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice.

Gahir SS, Piquette-Miller M.

Drug Metab Dispos. 2011 Mar;39(3):465-71. doi: 10.1124/dmd.110.034983. Epub 2010 Dec 2.

PMID:
21127142
45.

Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats.

Petrovic V, Piquette-Miller M.

Drug Metab Dispos. 2010 Oct;38(10):1760-6. doi: 10.1124/dmd.110.034470. Epub 2010 Jul 7.

PMID:
20610559
46.

Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer.

De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, Piquette-Miller M.

Mol Cancer Ther. 2010 Jun;9(6):1820-30. doi: 10.1158/1535-7163.MCT-10-0249. Epub 2010 Jun 8.

47.

Polymeric drug delivery systems for localized cancer chemotherapy.

De Souza R, Zahedi P, Allen CJ, Piquette-Miller M.

Drug Deliv. 2010 Aug;17(6):365-75. doi: 10.3109/10717541003762854. Review.

PMID:
20429844
48.

Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes.

Anger GJ, Piquette-Miller M.

J Pharmacol Exp Ther. 2010 Jul;334(1):21-32. doi: 10.1124/jpet.110.165639. Epub 2010 Mar 26.

PMID:
20348205
49.

Inflammation: extinguishing the fires within.

Vassileva V, Piquette-Miller M.

Clin Pharmacol Ther. 2010 Apr;87(4):375-9. doi: 10.1038/clpt.2010.10. No abstract available.

PMID:
20305667
50.

Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.

Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M.

Drug Metab Dispos. 2010 May;38(5):740-4. doi: 10.1124/dmd.109.030791. Epub 2010 Feb 16.

PMID:
20159988

Supplemental Content

Loading ...
Support Center